ADVANCED TREATMENT TECHNIQUES FOR NON-SMALL CELL LUNG CANCER – A REVIEW

Srikrishna T., Y. Prapurnachandra, P. Venugopalaih, L. Nichitha*, O. Nikhil, T. Thulasi, K. Harika and J. Chandrika

ABSTRACT

Lung cancer is the leading cause of cancer-related death not only in the United States, but worldwide. In North America, former smokers are more likely to develop lung cancer than current smokers. Nonetheless, a peak in lung cancer incidence is still expected in some countries, such as China, which has seen a dramatic increase in cigarette smoking rates over the last two decades. Approximately two-thirds of adult Chinese men smoke, accounting for one-third of all smokers globally. In the United States, non-small cell lung cancer accounts for 85% of all lung cancer cases. After a diagnosis of non-small cell lung cancer, accurate staging with computed tomography or positron emission tomography is critical for determining appropriate therapy. Surgical resection remains the most consistent and successful option for cure when it is feasible. However, nearly 70% of patients with lung cancer are diagnosed with locally advanced or metastatic disease. Chemotherapy is beneficial for patients with metastatic disease, and concurrent chemotherapy and radiation are recommended for stage III lung cancer. The introduction of new anticancer agents such as angiogenesis inhibitors, epidermal growth factor receptor inhibitors, and other anticancer agents is changing the present and future of this disease and will almost certainly increase the number of lung cancer survivors.

Keywords: Adenocarcinoma, squamous cell carcinoma, bronchioalveolar cell carcinoma, Electrocautery and targeted therapy.